GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » DeferredTaxAndRevenue

Modalis Therapeutics (TSE:4883) DeferredTaxAndRevenue : 円0.00 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Modalis Therapeutics's current deferred tax and revenue for the quarter that ended in Mar. 2024 was 円0.00 Mil.

Modalis Therapeutics DeferredTaxAndRevenue Historical Data

The historical data trend for Modalis Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modalis Therapeutics DeferredTaxAndRevenue Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
Get a 7-Day Free Trial - - - - -

Modalis Therapeutics Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Modalis Therapeutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Modalis Therapeutics (TSE:4883) Business Description

Traded in Other Exchanges
N/A
Address
16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics (TSE:4883) Headlines

No Headlines